SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-025777
Filing Date
2024-03-26
Accepted
2024-03-26 08:05:34
Documents
16
Period of Report
2024-03-25
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ea0202526-8k_allarity.htm   iXBRL 8-K 24498
2 PRESS RELEASE, DATED MARCH 25, 2024. ea020252601ex99-1_allarity.htm EX-99.1 12800
6 GRAPHIC image_001.jpg GRAPHIC 3163
7 GRAPHIC image_003.jpg GRAPHIC 3163
  Complete submission text file 0001213900-24-025777.txt   225804

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE allr-20240325.xsd EX-101.SCH 3015
4 XBRL LABEL FILE allr-20240325_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE allr-20240325_pre.xml EX-101.PRE 22359
19 EXTRACTED XBRL INSTANCE DOCUMENT ea0202526-8k_allarity_htm.xml XML 3728
Mailing Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108
Business Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41160 | Film No.: 24780971
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)